1 / 52

Diabetes in Pregnancy

Diabetes in Pregnancy. S Chandra. Epidemiology. Most common medical complication of Pregnancy affects 2-14% of pregnancies Gestational DM 90% Preexisting DM 10%. CHO Metabolism. Effects of Pregnancy mild fasting hypoglycemia; postprandial hyperglycemia

nita
Télécharger la présentation

Diabetes in Pregnancy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Diabetes in Pregnancy S Chandra

  2. Epidemiology • Most common medical complication of Pregnancy • affects 2-14% of pregnancies • Gestational DM 90% • Preexisting DM 10%

  3. CHO Metabolism • Effects of Pregnancy • mild fasting hypoglycemia; postprandial hyperglycemia • due to inc plasma volume in early gestation and inc fetal glucose utilization as pregnancy advances • progressive increase in tissue resistance to insulin • increase insulin secretion to maintain euglycemia • suppressed glucagon response • inc prolactin, cortisol • HPL has GH like effects

  4. Glucose Metabolism • Normal pregnancy : Diabetogenic state • increase in BG • insulin resistance • Early Pregnancy • Anabolic state • increase in maternal fat stores • decreased FFA concentration • decrease in insulin requirements

  5. Type I Diabetes • Abrupt onset • usually young age • occasionally occurs in 30’s or 40’s • lifelong requiremnent for insulin replacement • may have genetic predisposition for islet cell ab • concordance in MZ twins for dev of DM is 33% • suggests other factors also imp (environmental)

  6. Type 2 DM • Abnormalities of insulin sensitive tissues • decreased skeletal muscle and hepatic sensitivity to insulin • abnormal B cell response • inadequate response for a given degree of glycemia • usually older • increased BMI • insidious onset • strong genetic component • MZ twin data lifetime risk 58-100%

  7. Diagnosis of DiabetesNon Pregnant • Fasting plasma BG >99mg/dl • Casual plasma BG >200mg/dlImpaired Fasting Glucose • FPG 100-125 mg/dlImpaired Glucose Tolerance • normal FPG • 2 h 75gOGTT test with 140-199 mg/dl

  8. Classification and Risk Assessment Class DM onset Duration Vascular Dis Insulin Need Gestational Dm A1 Any Any - - A2 Any Any - + Pregestational DM B >20 <10 - + C 10-19 10-19 - + D <10 >20 + + F Any Any + + R Any Any + + T Any Any + + H Any Any + +

  9. Gestational Diabetes • Definition • CHO intolerance of variable severity first diagnosed in Pregnancy • Prevalence 2-4% • Risk Factors • maternal age >30 • Family history • glucosuria • prior macrosomia • previous unexplained stillbirth • ethnic group: Hispanic, Black, First Nations

  10. Gestational Diabetes • Screening • PC 50/Trutol • 1 hr after 50g load of glucose • >7.8mmol/l abnormal*140mg % • 15% of patients screen positive* value >10.3 190mg/dl diagnostic of GDM (no OGTT needed)

  11. Gestational Diabetes • Screening • 24-28 weeks routine • no need to fast • screen at 1st prenatal visit if hx of previous GDM • screen earlier (12-24 weeks ) if risk factors

  12. Gestational Diabetes • Diagnosis OGTT • 2 or more values greater than or equal to above cutoffs diagnostic of GDM • single abnormal value indicates CHO intolerance 2H 3 H Fasting 5.3 1h 10.6 2h 8.9 Fasting 5.3 1h 10.6/ 180 2h 9.2 /155 3h 8.1/140

  13. Gestational Diabetes Maternal Risks • birth trauma • Macrosomia, Polyhydromnios • operative delivery • 50% lifetime risk in developing Type II DM • recurrence risk of GDM is 30-50%

  14. Gestational Diabetes

  15. Gestational Diabetes Fetal Risks • no increase in congenital anomalies • increased risk of stillbirth if fasting+ pc hyperglycemia • macrosomia • birth trauma-shoulder dystocia and related complications

  16. Gestational Diabetes • Management • goal is to optimize BG levels to minimize risk of adverse perinatal outcomes • diet • exercise • insulin therapy

  17. Gestational Diabetes • Management : Diet • patients without fasting hyperglycemia • average 8000-9000 kj/day. • BMI>27 -- 25 kcal/kg/ideal body weight/d • BMI 20-26 -- 30 “ • BMI<20 -- 38 “

  18. Gestational Diabetes • Diet : general principles • 55% CHO 25% Protein 20% fat • Normal weight gain 10-12 kg • avoid ketosis • liberal exercise program to optimize BG control

  19. Gestational Diabetes • If persistent hyperglycemia after one week of diet control proceed to insulin • 6-14 weeks 0.5u/kg/day • 14-26 weeks 0.7u/kg/day • 26-36 weeks 0.9u/kg/day • 36-40weeks 1 u /kg/day

  20. Gestational Diabetes • If fasting hyperglycemia start with NPH hs • initial dose 6-8 U • if only pc hyperglycemia use humalog 2-4u ac the specific meal • adjust 2u/time 1 formula /time • BG target ac <5.3 2 h pc <6.7

  21. Gestational Diabetes • Intrapartum management • check bg hourly • maintain BG 4-6mmol/L

  22. Gestational Diabetes • Postpartum • often will not require insulin • if fasting hyperglycemia - more likely to develop persistent Diabetes • 6 weeks post partum 75g OGTT • yearly fasting BG • emphasize importance of maintaining N weight, exercise

  23. Gestational Diabetes Neonatal Risks • hypoglycemia 50% in macrosomic5-15% if N BG control in Pgy • Hyperbilirubinemia • polycythemia • hypocalcemia • hypomagnesiumia

  24. Preexisting Diabetes • Preconception Counselling • risk of NTD ~1-2% • Folic Acid 1-4 mg /day • BG 3.5-5.3 prior to meals • switch to MDI regimen (insulin ac meals and HS) • keep track of cycles

  25. Preexisting Diabetes • Normoglycemia prior to conception • ideally HBA1C 6% or less • Team approach • glucose monitoring qid • ACE contraindicated : should be D/C at conception or use Diltiazem instead • baseline HBA1C, 24h urine for protein Cr Cl , opthalmology review • switch from OHA to insulin

  26. Assess for end organ disease • assess for nephropathy - inc risk of PIH • Assess and treat retinopathy - may progress • assess for neuropathy • generally remains stable during pregnancy • assess and treat vasculopathy • CAD is a relative C/I for pregnancy

  27. Preexisting Diabetes • Maternal Risks • PIH /PET • polyhydramnios • preterm labour • operative delivery ~50% • birth trauma • infection • increase in insulin requirements • DKA

  28. Prexisting Diabetes

  29. Preexisting Diabetes • Fetal Risks • congenital anomalies 3X inc risk • unexplained stillbirth • shoulder dystocia • macrosomia • IUGR

  30. Preexisting Diabetes • Neonatal Risks • hypoglycemia • hypocalcemia • hyperbilirubinemia/polycythemia • idiopathic RDS • delayed lung maturity • prematurity • predisposition to diabetes

  31. Preexisting Diabetes • Congenital anomalies • 3x the general population risk • approaches the gen pop risk (2-3%) if optimal control in periconception period • related to glycemic control during embryogenesis

  32. CVS ASD/VSD,coarctation,transposition, cardiomegaly CNS anencephaly, NTD, microcephaly GI duodenal atresia, anorectal atresia, situs inversus GU renal agenesis Polycystic kidneys MSK caudal regression siren Congenital anomalies

  33. Preexisting Diabetes • Maternal Surveillance • Blood pressure • renal function * • urine culture ** • thyroid function • BG control HB A1C* • * q trimester • ** monthly

  34. Preexisting Diabetes • Fetal Surveillance • U/S for dating/viability ~ 8 weeks • Fetal anomaly detection • nuchal translucency 11-14w • maternal serum screen • anatomy survey 18-20 w • Fetal echo 22 w

  35. Multidose Insulin • breakfast 25% H • lunch 15% H • supper 25% H • hs 35% NPH • indicates insulin as a % of total daily dose Gabbe Obstet Gynecol 2003

  36. Insulin Therapy onset (h) peak duration • insulin analogs .25 0.5-1.5 6-8 • rapid acting 0.5 2-4 8-12 • intermediate 1-1.5 4-8 12-18

  37. Insulin Therapy • Insulin Pump • Allows insulin release close to physiologic • Use short acting insulin • 50-60% of total dose is basal rate • 40-50% given as boluses • Potential complications • Pump failure • Infection • Increased risk of DKA if above happens

  38. Peripartum Management • Withhold subcutaneous insulin from onset of labour or induction • IV D10 @50cc/h • IV short acting insulin in NS usually starting at 0.5-1u/h**10cc insulin in 100 cc NS(1U=10cc)

  39. Peripartum Management • insulin rate usually based on BG and pre-delivery insulin requirement • eg. For each 75-100 total units /24h of pre-delivery insulin, 1 unit per hour needed • measure capillary BG hourly VPG q2-3h • target: 4-6mmol/L

  40. Peripartum Management • Following delivery • stop insulin infusion • begin sub Q insulin • resume previous MDI schedule at 1/2 -2/3 the pre pregnancy dose • maintain IV D5W @50cc/h until oral feeds tolerated

  41. Oral Hypoglycemic agents • Traditionally not recommended in pregnancy • Recent RCT of oral glyburide vs insulin for GDM • 440 patients • BG measured 7x daily • Treatment started after 11 weeks gestation Langer NEJM 2000

  42. Oral Hypoglycemic agents Glyburide Insulin Achieved N BG 82% 88% LGA infants 12% 13% Macrosomia 7 4 C Section 23 24 Hypoglycemia 9 6 Preeclampsia 6 6 Anomalies 2 2 Langer NEJM 2000

  43. Fetal Surveillance • Goals • Minimize/eliminate the risk of fetal death • Early detection of fetal compromise • Prevent unnecessary premature delivery • Main benefit is the NPV of these tests • Provides reassurance that fetus with a N test unlikely to die in utero • Allow prolongation of pregnancy – fetal maturation

  44. Fetal Surveillance • Gestational Diabetic Diet controlled • Can start fetal surveillance at term (40 weeks) • GDM on insulin/Type II DM/ Type I DM • Start weekly BPP from 32 weeks • Consider earlier testing if • suboptimal control • Hypertension • vasculopathy

  45. Timing of Delivery GDM Diet controlled • Same as non diabetic • Offer induction at 41 weeks if undelivered GDM on Insulin/Type II/Type I • If suboptimal control deliver following confirmation of lung maturity if <39 weeks • Otherwise deliver by 40 weeks • Generally do not allow to go postterm

  46. Mode of Delivery • Macrosomic infants of diabetic mothers have higher rates of shoulder dystocia than non diabetic mothers • Ultrasound estimates of fetal weight become significantly inaccurate after 4000g • Reasonable to recommend C/S delivery if EFW is >4500g

  47. Diabetic Ketoacidosis • 5-10% of pregnant Type 1 pts • Risk factors • New onset DM • Infection • Insulin pump failue • Steroids • B mimetics • Fetal mortality 10%

  48. Diabetic Ketoacidosis • Management • ABC’s and ABG • Assess BG, ketones electrolytes • Insulin • .2-.4U/Kg loading and 2-10U/h maintenance • Begin 5% dextrose when BG is 14 mmol/l • When potassium is N range begin 20mEq/h • Rehydration isotonic NaCl • 1L in 1st hour • .5-1l/h over 2-4h • 250cc/h until 80% replaced • Replace Bicarb and phosphate as needed

More Related